Takeover Agreement with Alcon Sparks Sharp Weekly Gains for STAAR Surgical

STAAR Surgical Company (NASDAQ:STAA) is one of the 11 Best Short-Term Stocks to Invest in.

Significant price movements were noted this week following the announcement of a takeover agreement from Alcon.

Takeover Agreement with Alcon Sparks Sharp Weekly Gains for STAAR Surgical

A surgeon examining a patient’s eyes with a microscope, focusing on locating defects in vision.

California-based company, STAAR Surgical Company develops, manufactures, and markets implantable, foldable Collamer® lenses and delivery systems for cataract and refractive eye surgery. The company has sold over 3 million lenses globally and consistently serves patients requiring visual clarity with minimally invasive procedures. Business operations span more than 75 countries.

On August 5, 2025, Alcon, a global leader in eye care, agreed to acquire STAAR Surgical. The terms of the agreement state that Alcon will purchase all outstanding shares of STAAR common stock for $28 per share. The offer represents an approximate 59% premium to STAAR’s 90-day Volume Weighted Average Price (VWAP) and a substantial 51% premium to the closing price of STAAR common stock as of August 4, 2025. The total equity value of the transaction is approximately $1.5 billion, and it is expected to be carried out in cash.

The acquisition primarily includes STAAR Surgical Company’s EVO family of ICL lenses. Alcon aims to integrate it to provide a leading surgical vision correction solution for individuals with moderate to high myopia.

STAAR Surgical Company’s stock price spiked 45.43% this week and signals a powerful but limited-time opportunity for short-term investors, despite a 32.37% annual decline.

READ NEXT: 12 Best REIT Stocks to Buy Right Now and 10 Stocks with Huge Catalysts on the Horizon

Disclosure. None.